Skeletal muscle mass and strength are critical in helping prevent falls, fractures, and disability. Yet, they continue to decline during the menopause transition. A new study showed that the prolonged use (defined as ≥13 mo) of hormone therapy (HT) was associated with higher muscle mass and less chance of sarcopenia. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS).
Sarcopenia is defined as a loss of skeletal muscle mass and strength that mostly affects older people. In addition to increasing the risk of falls and fractures, it can also increase the risk of diabetes and cardiovascular disease. Although sarcopenia is highly prevalent in postmenopausal women, there is no definitive evidence supporting its link with the decline in estrogen during the menopause transition. Multiple small-scale studies have been conducted to assess the association between HT use and muscle mass, but their results have been inconsistent.
This new study, which included more than 4,200 postmenopausal women, is one of the few large-scale studies known to assess the link between use of HT and muscle loss in postmenopausal women. More specifically, it focused on the duration of HT use and its effect on muscle mass and the prevalence of sarcopenia.
On the basis of study results, which appear in the article “The association between hormone therapy and sarcopenia in postmenopausal women: the Korea National Health and Nutrition Examination Survey, 2008-2011,” the researchers concluded that prolonged use of HT is associated with higher muscle mass and a lower prevalence of sarcopenia in postmenopausal women.
Source: Read Full Article
